CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This study is testing a new type of genetically engineered immune cell therapy — called CAR T cells — that simultaneously targets two proteins (CD19 and CD20) on B-cell lymphomas. It is designed for patients whose lymphoma has come back or stopped responding to other treatments. **You may be eligible if...** - You are 18–80 years old - You have been diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma (cancer has returned or is not responding) - Your cancer expresses CD19 and/or CD20 proteins (confirmed by standard testing) - You have adequate immune cell counts (CD3 count ≥50 cells/mm³) - Your cancer has not spread to the brain or spinal fluid **You may NOT be eligible if...** - You have active brain or spinal cord involvement by lymphoma - You have serious uncontrolled infections - You have severe organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.